# Morphocell Technologies

> Morphocell Technologies is a Montreal-area regenerative medicine company building allogeneic, stem cell-derived engineered tissues to treat severe organ deficiencies, starting with the liver. Its lead program, ReLiver, is a transiently implanted engineered liver tissue made from induced pluripotent stem cells (iPSCs) intended to treat acute and acute-on-chronic liver failure without immunosuppression. Spun out of CHU Sainte-Justine in 2018, the company has raised US$50 million in Series A funding and runs vertically integrated operations spanning discovery, cell manufacturing and preclinical development.

- **Founded:** 2018
- **Headquarters:** Laval, Quebec, Canada
- **Founders:** Massimiliano Paganelli (Co-Founder, President & CEO), Claudia Raggi (Co-Founder, Chief Scientific Officer)
- **Team size:** 44 employees
- **Products:** ReLiver, Engineered tissue platform
- **Notable:** Raised US$50M total Series A (US$40M initial close in Feb 2024, US$10M add-on in Dec 2025), Grew to a 44-person team across Montreal, Cambridge (Boston) and Toronto, Spun out of CHU Sainte-Justine's liver tissue engineering lab in 2018

## Products & services

- **ReLiver** — Lead therapeutic product: an allogeneic, iPSC-derived engineered liver tissue for transient implantation to treat acute and acute-on-chronic liver failure. It aims to improve survival, treat hepatic encephalopathy and accelerate the recipient's own liver regeneration, all without immunosuppression.
- **Engineered tissue platform** — A platform that turns allogeneic induced pluripotent stem cells (iPSCs) into engineered tissues designed to replace or supplement failing organ function, with vertically integrated discovery, cell manufacturing and preclinical development.

## Achievements

- Raised US$50M total Series A (US$40M initial close in Feb 2024, US$10M add-on in Dec 2025)
- Grew to a 44-person team across Montreal, Cambridge (Boston) and Toronto
- Spun out of CHU Sainte-Justine's liver tissue engineering lab in 2018
- Granted its first US patent by the USPTO for iPSC-derived hepatocyte differentiation methods
- Extended operational runway to over three years following the add-on financing
- Establishing its first European subsidiary in Italy

## Latest updates

- **2025-12** — Completed US$50M Series A after a US$10M add-on led by Investissement Quebec and CDP Venture Capital; announced plans for a first European subsidiary in Italy.
- **2024-04** — Announced US$40M Series A led by Genson Capital to advance ReLiver toward first-in-human trials.
- **2024-02** — Initial close of the Series A round.

## Links

- Website: https://morphocell.com
- LinkedIn: https://www.linkedin.com/company/morphocell-technologies
- Twitter/X: https://twitter.com/morphocelltech
- YouTube: https://www.youtube.com/watch?v=aHb87d9ukUE

---

Profile page: https://yespress.io/morphocell-technologies
Published by YesPress — https://yespress.io
Last updated: 2026-06-13